"The LEAP assay addresses an important gap in the field, namely providing a non-invasive solution in recording high quality action potentials from cardiac cells using a high throughput format. The LEAP assay may be a game changer in the field of safety and cardiotoxicity testing."
Bernard Fermini, Ph.D.
Chief Scientific Officer
Vice-President of Safety & Toxicology Assessment
Cardiac Extracellular Action Potentials
Axion's patent-pending Local Extracellular Action Potential (LEAP) assay allows you to record extracellular action potential waveforms, which are stable for 10 to 20 minutes or more. The new LEAP assay signal allows quantification of action potential morphology and characterization of complex repolarization irregularities such as early afterdepolarizations (EADs). LEAP is label-free and doesn't disrupt the underlying biology, meaning you can focus on the pharmacology and not on dye-drug or dye-biology interactions.
The inability to predict a drug’s cardiovascular liability prior to clinical trials or launch has resulted in numerous costly late stage drug development failures and market withdrawals. The aim of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is to update the existing cardiac safety testing paradigm to better evaluate arrhythmia risk . One proposed test of the CiPA panel is a microelectrode array (MEA) assay that tracks drug-induced changes to beating heart cells in a dish.
The Maestro MEA system played a pivotal role in the CiPA Myocyte studies. LEAP technology aids automated arrhythmia detection and classification in cardiomyocyte MEA assays.
Dedicated stimulation electrodes in Axion's MEA plates for robust stimulation capture
Cardiomyocytes cultured on MEAs create an accessible platform for studying heart beats in a dish. Cardiomyocyte assays rely on evaluation of parameters, such as repolarization timing, that are tightly coupled to beat rate. Controlling beat rate allows you to increase physiological relevance and reduce well-to-well variability. Furthermore, the ability to systemically vary beat rate enables detection of use dependent (i.e. beat rate dependent) drug effects.
Lumos™ optical stimulation system for multiwell MEA plates
The Lumos optical stimulation system delivers precisely controlled light to each well of a 48-well microplate (24-well Lumos coming soon). The Maestro MEA platform provides non-invasive electrical activity recordings across each cultured cardiomyocyte network. Together, these devices seamlessly pair to unlock entirely new assay capabilities, all in a high-throughput format. Combine the Lumos and Maestro to precisely control cardiomyocyte beat rate while simultaneously recording electrical responses.
Built on Axion’s latest chip technology, BioCore v4, the next generation Maestro MEA systems makes it even easier to perform measurements from excitable cells in your own lab.
With “one button setup,” the cell environment automatically adjusts on plate docking, and plate usage is automatically logged for convenient experiment tracking. Both Maestro Pro and Edge run Axion’s most advanced data acquisition and analysis software, AxIS Navigator.